Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.
Jasmin Beate Kuemmerle-DeschnerTilmann KallinichJoerg Christoph HenesBirgit Kortus-GötzePrasad T OommenJuergen RechTobias KrickauFrank Weller-HeinemannGerd HorneffAleš JandaIvan FoeldvariCatharina SchuetzFrank DresslerMichael BorteMarkus HufnagelFlorian MeierMichael FieneIoana AndreicaJulia Weber-ArdenNorbert BlankPublished in: RMD open (2024)
Data from this analysis confirm the long-term safety and effectiveness of canakinumab for the treatment of CAPS, FMF, TRAPS and MKD/HIDS.